PTEN and cancer: Two large retrospective studies showed indeed that PTEN loss (defined as less than 10% of cancer cells presenting positive staining) was associated with lack of response to abiraterone [40]; however, PTEN loss cancers had the same chance to respond to docetaxel as PTEN normal tumors [46].